Carret Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Carret Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$836K	Sell	58,300 -1,200	-2%	-$13.3K	0.07%	171
2026 Q1	$555K	Buy	59,500 +5,500	+10%	+$49.6K	0.05%	202
2025 Q4	$484K	Sell	54,000 -3,040	-5%	-$28.8K	0.05%	209
2025 Q3	$542K	Buy	57,040 +17,400	+44%	+$175K	0.05%	196
2025 Q2	$349K	Buy	39,640 +3,500	+10%	+$28.4K	0.04%	220
2025 Q1	$271K	Buy	+36,140	New	+$287K	0.03%	237

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carret Asset Management's ZVRA Position: Q2 2026 in Review

Carret Asset Management reduced its Zevra Therapeutics (ZVRA) stake by 2% in Q2 2026, selling an estimated $13.3K and leaving 58,300 shares worth $836K. The position accounts for 0.07% of the portfolio, ranked #171.

Carret Asset Management first reported a position in ZVRA in Q1 2025 and has held it in 6 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Carret Asset Management held 58,300 shares of Zevra Therapeutics worth $836K as of Q2 2026.
Carret Asset Management sold 1,200 Zevra Therapeutics shares in Q2 2026, an estimated $13.3K.
Zevra Therapeutics made up 0.07% of Carret Asset Management's portfolio in Q2 2026, its #171 holding.
Carret Asset Management first reported a position in Zevra Therapeutics in Q1 2025 and has held it in 6 quarters since.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Carret Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.